Drugs / CPO107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04853329 | Dec 2021 → Jan 2023 | B-cell non-Hodgkin lymphoma | Conjupro Biotherapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPO107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853329 ↗ |
| Route | Intravenous | “Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non Hodgkins Lymphoma” NCT04853329 ↗ |